At the year 11 visit, none of 1,913 women given the bivalent HPV vaccine in Costa Rica had new HPV 16/18 precancer of the cervix, against 34 of 2,233 unvaccinated women.
The Costa Rica Vaccine Trial, publicly funded and begun before the HPV vaccines were licensed, randomised women aged 18 to 25 between June 2004 and December 2005 to three doses of the bivalent HPV 16/18 vaccine or a hepatitis A control vaccine, followed them for 4 years, and then followed the vaccinated group for 7 more years against a new unvaccinated control group. The primary outcome was HPV 16/18-associated CIN2 or worse.
Protection from the bivalent HPV vaccine against the precancers that lead to cervical cancer lasted more than a decade.
Shares Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN), HPV bivalent vaccine (types 16 and 18), National Cancer Institute (NIH), Cervical cancer.
Shares Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN), HPV bivalent vaccine (types 16 and 18), National Cancer Institute (NIH), Cervical cancer.
Shares HPV bivalent vaccine (types 16 and 18), Cervical cancer.
Shares HPV bivalent vaccine (types 16 and 18), Cervical cancer.
Shares Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN), Cervical cancer.
Shares HPV bivalent vaccine (types 16 and 18), Cervical cancer.
Shares Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN), Cervical cancer.
Shares Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN), HPV bivalent vaccine (types 16 and 18), Cervical cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/